ROIV peer analysis
Roivant Sciences (ROIV) against its competitors: price, today's move, 1-year return and market value side by side.
ROIV and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ALNY Alnylam | $155.42 | -0.79% | -64.23% | $20.82B |
| BIIB Biogen | $248.35 | 1.81% | 61.87% | $36.71B |
| BNTX BioNTech | $87.00 | 1.33% | -15.89% | $22.00B |
| GMAB Genmab | $53.89 | 2.17% | 84.61% | $33.63B |
| INCY Incyte | $120.00 | 1.69% | 13.53% | $24.46B |
| JAZZ Jazz Pharmaceuticals | $237.00 | 4.26% | 72.72% | $15.21B |
| MRNA Moderna | $256.92 | 6.40% | 990.48% | $102.57B |
| REGN Regeneron | $900.00 | -0.32% | 39.71% | $93.10B |
| UTHR United Therapeutics | $562.02 | -0.65% | 25.61% | $23.94B |
| VRTX Vertex | $548.00 | 1.01% | 31.41% | $138.94B |
| ROIV Roivant Sciences | $38.88 | 6.17% | 92.19% | $28.08B |
- ROIV's peers: ALNY (Alnylam), BIIB (Biogen), BNTX (BioNTech), GMAB (Genmab), INCY (Incyte), JAZZ (Jazz Pharmaceuticals), MRNA (Moderna), REGN (Regeneron).
Updated 2026-11-07 11:53 UTC